Accelerated Path to Cures provides a transformative perspective on the power of combining advanced computational technologies, modeling, bioinformatics and machine learning approaches with nonclinical and clinical experimentation to accelerate drug development. This book discusses the application of advanced modeling technologies, from target identification and validation to nonclinical studies in animals to Phase 1-3 human clinical trials and post-approval monitoring, as alternative models of drug development. As a case of successful integration of computational modeling and drug development, we discuss the development of oral small molecule therapeutics for inflammatory bowel disease, from the application of docking studies to screening new chemical entities to the development of next-generation in silico human clinical trials from large-scale clinical data. Additionally, this book illustrates how modeling techniques, machine learning, and informatics can be utilized effectively at each stage of drug development to advance the progress towards predictive, preventive, personalized, precision medicine, and thus provide a successful framework for Path to Cures.
"synopsis" may belong to another edition of this title.
Dr. Josep Bassaganya-Riera is a serial entrepreneur and innovator who has served as the Director of the Nutritional Immunology and Molecular Medicine Laboratory (NIMML) at the Biocomplexity Institute of Virginia Tech since 2002. The NIMML tackles unsolved challenges in complex human diseases with unmet clinical needs. His research has received over $55 million in competitive R&D funding to combine advanced computational technologies with preclinical and clinical experimentation. The NIMML translates novel scientific discoveries into commercial applications that address unmet patient or consumer needs. Dr. Bassaganya-Riera has published over 150 peer-reviewed publications in reputable biomedical journals, founded 3 successful biotech companies (Pervida, Biotherapeutics and Landos Biopharma), and was recently named 2017 Innovator of the Year by the Roanoke-Blacksburg Technology Council. Dr. Bassaganya-Riera, and his companies have been active members of a statewide group that supports the planning behind the Governor’s 2015 Virginia Bioscience Initiative. This initiative calls for Virginia to be in the top three pharmaceutical regions by 2023. Dr. Bassaganya-Riera was a featured presenter at the Governor’s Forum on Bio and Big Data.
Accelerated Path to Cures provides a transformative perspective on the power of combining advanced computational technologies, modeling, bioinformatics and machine learning approaches with nonclinical and clinical experimentation to accelerate drug development. This book discusses the application of advanced modeling technologies, from target identification and validation to nonclinical studies in animals to Phase 1-3 human clinical trials and post-approval monitoring, as alternative models of drug development. As a case of successful integration of computational modeling and drug development, we discuss the development of oral small molecule therapeutics for inflammatory bowel disease, from the application of docking studies to screening new chemical entities to the development of next-generation in silico human clinical trials from large-scale clinical data. Additionally, this book illustrates how modeling techniques, machine learning, and informatics can be utilized effectively at each stage of drug development to advance the progress towards predictive, preventive, personalized, precision medicine, and thus provide a successful framework for Path to Cures.
"About this title" may belong to another edition of this title.
Seller: Brook Bookstore On Demand, Napoli, NA, Italy
Condition: new. Questo è un articolo print on demand. Seller Inventory # 2b7e21cacd349660eb577ab4cf87e9e2
Quantity: Over 20 available
Seller: GreatBookPrices, Columbia, MD, U.S.A.
Condition: New. Seller Inventory # 30584355-n
Seller: BargainBookStores, Grand Rapids, MI, U.S.A.
Hardback or Cased Book. Condition: New. Accelerated Path to Cures. Book. Seller Inventory # BBS-9783319732374
Seller: Basi6 International, Irving, TX, U.S.A.
Condition: Brand New. New. US edition. Print on demand title. Delivery takes 20-25 days. Excellent Customer Service. Seller Inventory # POD-253662
Seller: GreatBookPrices, Columbia, MD, U.S.A.
Condition: As New. Unread book in perfect condition. Seller Inventory # 30584355
Seller: StainesBook, Weybridge, SURRE, United Kingdom
Condition: New. Seller Inventory # SpeedList-SL614
Quantity: 2 available
Seller: Ria Christie Collections, Uxbridge, United Kingdom
Condition: New. In English. Seller Inventory # ria9783319732374_new
Quantity: Over 20 available
Seller: GreatBookPricesUK, Woodford Green, United Kingdom
Condition: New. Seller Inventory # 30584355-n
Quantity: Over 20 available
Seller: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Germany
Buch. Condition: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Accelerated Path to Cures provides a transformative perspective on the power of combining advanced computational technologies, modeling, bioinformatics and machine learning approaches with nonclinical and clinical experimentation to accelerate drug development. This book discusses the application of advanced modeling technologies, from target identification and validation to nonclinical studies in animals to Phase 1-3 human clinical trials and post-approval monitoring, as alternative models of drug development. As a case of successful integration of computational modeling and drug development, we discuss the development of oral small molecule therapeutics for inflammatory bowel disease, from the application of docking studies to screening new chemical entities to the development of next-generation in silico human clinical trials from large-scale clinical data. Additionally, this book illustrates how modeling techniques, machine learning, and informatics can be utilized effectively at each stage of drug development to advance the progress towards predictive, preventive, personalized, precision medicine, and thus provide a successful framework for Path to Cures. 82 pp. Englisch. Seller Inventory # 9783319732374
Seller: GreatBookPricesUK, Woodford Green, United Kingdom
Condition: As New. Unread book in perfect condition. Seller Inventory # 30584355
Quantity: Over 20 available